Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.60 |
| ▸ | GRM6 | O15303 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | GSR | P00390 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.60 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709483 | 1.00 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Thioacetamide SCHEMBL711295 | 0.89 | DPP4 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Thioacetamide SCHEMBL711294 | 0.89 | DPP4 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29833669 | 0.82 | BLM (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL1534035 | 0.82 | CTSD (0.44) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL27741548 | 0.82 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL564272 | 0.82 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL1534041 | 0.82 | CTSD (0.44) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL288407 | 0.82 | BLM (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL11478144 | 0.82 | BLM (0.58) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318503-B2 | Method for determining the amount of conjugated taxane in polyglut acid-taxane conjugates | CELL THERAPEUTICS, INC. (US) | 2012-11-27 | — | — | US | claimed |
| EP-1967854-B1 | Method for determining the amount of conjugated taxane in polyglutamic acid-taxane conjugates | CELL THERAPEUTICS EUROPE SRL (IT) | 2010-11-03 | — | — | EP | claimed |
| US-20100151582-A1 | METHOD FOR DETERMINING THE AMOUNT OF CONJUGATED TAXANE IN POLYGLUT ACID-TAXANE CONJUGATES | CELL THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| WO-2008107174-A1 | METHOD FOR DETERMINING THE AMOUNT OF CONJUGATED TAXANE IN POLYGLUT ACID-TAXANE CONJUGATES | CELL THERAPEUTICS INC. (US) | 2008-09-12 | — | — | WO | claimed |
| EP-1967854-A1 | Method for determining the amount of conjugated taxane in polyglutamic acid-taxane conjugates | Cell Therapeutics Europe S.R.L. (IT) | 2008-09-10 | — | — | EP | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117440833-A | anti-HER 2 antibody-drug conjugates and uses thereof | AMBRX公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10792342-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2020-10-06 | — | — | US | disclosed |
| US-8124073-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2012-02-28 | — | — | US | disclosed |
| CN-101918026-A | Modified insulin polypeptides and their uses | AMBRX INC | 2010-12-15 | — | — | CN | disclosed |
| US-20080226658-A1 | Lysosomal conjugate for use in treatment of fabry, gaucher or niemann-pick diseases | GENZYME CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| US-7341720-B2 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1877099-A2 | PEG AND POLYSIALIC LYSOSOMAL ENZYME CONJUGATES VIA ACID LABILE LINKERS FOR THERAPEUTIC TARGETING | Genzyme Corporation (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20060228348-A1 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION | 2006-10-12 | — | — | US | disclosed |
| WO-2006108052-A2 | PEG AND POLYSIALIC LYSOSOMAL ENZYME CONJUGATES VIA ACID LABILE LINKERS FOR THERAPEUTIC TARGETING | GENZYME CORPORATION (US) | 2006-10-12 | — | — | WO | disclosed |
| US-4745161-A | Soluble and biodegradable polyamino acid activated for bonding of biologically active compound | CESKOSLOVENSKA AKADEMIE VED (CS) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792342-B2 | Targeting of glycoprotein therapeutics | SIGLEC7, LAMP2, ASGR1 | GRM8 1160/4885GRM6 455/4885GRIN2D 3024/4885 |
| US-20060228348-A1 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GAA, MAN2B1, GBA1 | GRM8 1553/4885GRM6 561/4885GRIN2D 2946/4885 |
| US-20080226658-A1 | Lysosomal conjugate for use in treatment of fabry, gaucher or niemann-pick diseases | GAA, GBA1, MAN2B1 | GRM8 2241/4885GRM6 1248/4885GRIN2D 2818/4885 |
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP3 | GRM8 910/4885GRM6 724/4885GRIN2D 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.